Cover Image
市場調查報告書

大正製藥:產品平台分析

Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 259359
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
大正製藥:產品平台分析 Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年12月15日 內容資訊: 英文 40 Pages
簡介

大正製藥是開發·製造·銷售各種醫藥產品的製藥公司。該公司產品網羅了從處方藥到一般成藥,相當廣泛。

本報告提供大正製藥的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

大正製藥的基本資料

  • 大正製藥概要
  • 主要資訊
  • 企業資料

大正製藥:R&D概要

  • 主要的治療範圍

大正製藥:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

大正製藥:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

大正製藥:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

大正製藥:藥物簡介

  • TS-091
  • luseogliflozin
  • TS-111
  • TS-121
  • MGS-0028
  • Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis
  • Small Molecules to Inhibit 50S RNA for Bacterial Infections
  • TASP-0415914
  • TKM-0150
  • TASP-0376377

大正製藥:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

大正製藥:最近的開發平台趨勢

大正製藥:暫停中的計劃

大正製藥:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • EPI-2010
  • TS-033
  • parogrelil
  • TS-022

大正製藥:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06655CDB

Summary

Global Markets Direct's, 'Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Taisho Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Taisho Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Taisho Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Taisho Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Taisho Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Taisho Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Taisho Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Taisho Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Taisho Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Taisho Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Taisho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Taisho Pharmaceutical Co., Ltd. Snapshot
    • Taisho Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Taisho Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Taisho Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Taisho Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Taisho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Taisho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Taisho Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Taisho Pharmaceutical Co., Ltd. - Drug Profiles
    • TS-091
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • luseogliflozin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TS-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TS-121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGS-0028
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 50S RNA for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TASP-0415914
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TKM-0150
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TASP-0376377
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Taisho Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Taisho Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Taisho Pharmaceutical Co., Ltd. - Dormant Projects
  • Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • EPI-2010
      • TS-033
      • parogrelil
      • TS-022
  • Taisho Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Taisho Pharmaceutical Co., Ltd., Key Information
  • Taisho Pharmaceutical Co., Ltd., Key Facts
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • Taisho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Taisho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • Taisho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • Taisho Pharmaceutical Co., Ltd. - Phase II, 2014
  • Taisho Pharmaceutical Co., Ltd. - Phase I, 2014
  • Taisho Pharmaceutical Co., Ltd. - Preclinical, 2014
  • Taisho Pharmaceutical Co., Ltd. - Discovery, 2014
  • Taisho Pharmaceutical Co., Ltd. - Unknown, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Target, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Taisho Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014
  • Taisho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014
  • Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014
  • Taisho Pharmaceutical Co., Ltd., Other Locations
  • Taisho Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • Taisho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top